APOLLO HOSPITALS ENTERPRISE LTD. - 508869 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
As per annexure enclosed31-05-2022
31-05-2022
Street looking beyond Apollo Hospitals' disappointing Q4 performance
Based on sum-of-the-parts valuation, some analysts have pegged their target price between Rs 4,900-5,00027-05-2022
APOLLO HOSPITALS ENTERPRISE LTD. - 508869 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
As per annexure enclosed27-05-2022
APOLLO HOSPITALS ENTERPRISE LTD. - 508869 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Dear Sir, Sub: Intimation in terms of Regulation 39(3) of the SEBI (LODR) Regulations, 2015 (Regulations) regarding loss of share certificate. This is to inform you that the Company has received intimation from shareholder on May 26, 2022 regarding loss of share certificate. In accordance with Regulation 39(3) of the Regulations, the details of the said share certificates are as given below: Folio No. Name of the Shareholder(s) No of equity shares held Share Certificate No. Distinctive Nos. 2760 Ismail M M 3000 352761 4769429 to 4772428 6219 Prakash K R B 2000 356221 6511965 to 6513964 This is for your information.26-05-2022
Q4FY22 Quarterly Result Announced for Apollo Hospitals Enterprise Ltd.
Apollo Hospitals Enterprise declares Q4FY22 result: Q4 FY22 Consolidated Revenues of Rs 35,464 mio (growth of 24% yoy). Q4 FY22 Consolidated EBITDA (Post Ind AS 116) of Rs 4,632 mio. New Hospitals (excl Proton) reported an EBITDA of Rs 826 mio in Q4 FY22 as compared to an EBITDA of Rs 677 mio in Q4 FY21. Proton reported EBITDA (Post Ind AS 116) of Rs 139 mio in Q4 FY22 as compared to EBITDA of Rs 25 mio in Q4 FY21. AHLL reported EBITDA (Post Ind AS 116) of Rs 371 mio in Q4 FY22 as compared to EBITDA Rs 305 mio in Q4FY21. Consolidated PAT of Rs 901 mio in Q4 FY22. PAT before adjusting for tax (business combination U/s Ind AS 103) is Rs 1,783 mio. Ind-AS 116 on operating lease impacted reported PBT in Q4FY22 to the extent of Rs 119 mio. Q4FY22 occupancy across the group was at 4,604 beds (58% occupancy) as compared to 4,631 beds (63% occupancy) in Q4FY21. The Q4FY22 occupancy in mature hospitals was at 3,284 beds (60% occupancy). New hospitals had an occupancy of 1,320 beds (55%) occupancy) in Q4FY22. Inpatient Volumes across the group increased by 7% from 108,169 to 115,902. ARPOB (excluding vaccination) was at Rs 48,510 Vs Rs 43,239 registering a growth of 12% in Q4 FY22 as compared to the same period previous year. Result PDF26-05-2022
APOLLO HOSPITALS ENTERPRISE LTD. - 508869 - Announcement under Regulation 30 (LODR)-Investor Presentation
As per annexure enclosed26-05-2022
APOLLO HOSPITALS ENTERPRISE LTD. - 508869 - Board recommends Dividend
Apollo Hospitals Enterprise Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 25, 2022, inter alia, has recommended a dividend of Rs. 11.75 per share (235% of face value of Rs. 5/- per share) for the financial year ended March 31, 2022, on the paid up equity shares of the Company to the members, subject to members approval at the forthcoming Annual General Meeting.26-05-2022
Apollo Hospitals Q4 net profit falls 46% to Rs 90 cr; revenue jumps 24%
Apollo Hospitals Enterprises on Wednesday said its consolidated profit after tax declined by 46 per cent to Rs 90 crore for the fourth quarter ended on March 31, 2022. The health care provider had reported a PAT of Rs 168 crore in the January-March quarter of 2020-21 fiscal. Revenue from operations rose to Rs 3,546 crore in the fourth quarter as compared with Rs 2,868 crore in the year-ago period. For the full year ended March 31, 2022 the company posted a consolidated net profit of Rs 1,056 crore as against Rs 150 crore in the 2020-21 fiscal. Revenue from operations stood at Rs 14,663 crore for the last fiscal while the same was at Rs 10,560 crore in FY21. The company's board recommended a dividend of Rs 11.75 per share of face value of Rs 5 each for the financial year ended March 31, 2022, it added. The company said its board also approved the re-appointment of Prathap C Reddy as a whole time director designated as an Executive Chairman for a period of two years with effect fro25-05-2022